Ionis Pharmaceuticals reported positive top-line data from the Phase 1/2a trial of its ASO.
Scientists found FUS interacts with Argonaute, miRNAs, and targets mRNAs to quell gene expression.
In neuronal cell culture, extracts from AD mouse brain seeded intracellular clumps of Aβ oligomers. Like prions, the inclusions persisted through generations of cells.
The agency is accepting comments on a draft guidance that updates its recommendations for early AD trials, as well as on its first-ever guidance for ALS drug development.
Activity-dependent secretion accounts for majority of extracellular α-synuclein in brains of healthy mice.
Researchers claim that young cases of cerebral amyloid angiopathy may have been caused by contaminated surgical equipment.
Health records from 31 million French people suggest that drinking to excess is a major risk factor for early onset dementia.
Longitudinal neuroimaging of DIAN participants reveals that in most regions of the brain affected by AD pathology, Aβ accumulates first, then metabolism slows, then the brain shrinks.
The PDE9A inhibitor BI 409306 failed to improve cognition in Phase 2 trials.
A variant squelching expression of PAD4 enzyme reportedly drives up ALS risk by reducing aggregation of RNA-binding proteins.
First presented at CTAD 2017, results suggest good safety, hint at efficacy for this serotonin-targeted drug.
Its Challenge Network seeks to attract new investigators and new ideas to focus on cross-disease cell biology.
The French biochemist was part of the team that identified tau as the major component of neurofibrillary tangles in 1985.
Researchers claim that amyloid deposits completely vanish when BACE1 expression is gradually shut down in adult, plaque-ridden mice.
Two transcriptional profiles of astrocytes in healthy old mice record a surge in reactive and inflammatory gene expression.